



Pergamon

Bioorganic & Medicinal Chemistry Letters 8 (1998) 161–164

BIOORGANIC &
MEDICINAL CHEMISTRY
LETTERS

ENZYMATIC FUCOSYLATIONS OF NON-NATURAL SIALYLATED TYPE-I TRISACCHARIDES WITH RECOMBINANT FUCOSYL-TRANSFERASE-III

Gabi Baisch, Reinhold Öhrlein*, Markus Streiff

NOVARTIS PHARMA AG, Schwarzwaldallee 211, CH-4002 Basle, Switzerland

Received 13 October 1997; accepted 26 November 1997

ABSTRACT

Recombinant fucosyl-transferase-III (Lewis type enzyme) is used to prepare a series of non-natural sialyl-Lewis^a derivatives on a preparative scale. The enzyme tolerates a wide range of acceptors which have the natural N-acetyl group of the glucosamine moiety replaced by substituted aromatic and hetero-aromatic amides. © 1998 Elsevier Science Ltd. All rights reserved.


Molecular glycobiology has progressed considerably in recent years¹ and glycoconjugates are now found worthwhile targets for drug development in order to treat severe carbohydrate-based disorders^{2,3,4}. This class of highly homofunctional compounds is best tackled synthetically by a combined chemo-enzymatic approach^{5,6}.

In vivo, glycosyl-transferases transfer a monosaccharide unit from a nucleotide-activated donor to a growing oligosaccharide chain with rigorous stereo- and regioselectivity. We could recently show that $\beta(1-4)$ galactosyl-transferase⁷, recombinant $\alpha(2-3)$ sialyl-transferase⁸ and fucosyl-transferase-VI (fuc-T)⁹ tolerate a surprisingly wide range of non-natural acceptor substrates and form the desired oligosaccharides with the proper stereochemistry in the presence of their respective donor substrates. Furthermore fuc-T III and fuc-T VI were demonstrated to recognize fucose-donors which had the natural guanosine replaced by various other nucleosides¹⁰. Also alterations of the fucose part of the donor were tolerated¹¹ which was first shown with a fuc-T mixture isolated from human milk¹². In addition both non-natural donors and non-natural acceptors are processed by recombinant fuc-T VI at the same time and are assembled according the parent substrates¹³.

Here we want to report our investigations concerning the synthetic scope of recombinant fuc-T III (EMBL accession no. X53578)¹⁴. *In vivo*, the enzyme transfers a fucose unit from the activated donor guanosine-

E-mail: REINHOLD.OEHRLEIN@pharma.novartis.com.











diphosphofucose (GDP-fuc) onto the 4-OH group of the N-acetylglucosamine moiety of a type I sugar chain in an α -mode to form Lewis^a or sialyl-Lewis^a structures, respectively (see scheme and table). A number of sialylated type-I sugars **1** have been prepared enzymatically (see preceding paper). They have the natural N-acetyl group of the GlcNAc-unit replaced by large, relatively unpolar (entries 4,7), highly polar aromatic (entries 3,5,6) or heterocyclic amides (entries 8,9,10). Although a few very little alterations at the N-acyl position had been reported for the milk enzyme previously¹⁵, surprisingly, all the trisaccharides **1** have been accepted by the recombinant, homofunctional transferase. All the trisaccharides **1** are fucosylated by fuc-T III at the 4-OH group of the N-acyl glucosamine subunits in the expected α -mode despite the great steric bulk of the amino substituent. This is proven by the MS-, ¹H NMR- and ¹³C NMR-data obtained from the new tetrasaccharides **3**. These data are in good agreement with the data of the parent compound (entry 1) and literature reports¹⁵. The shifts of selected nuclei have been included in the table. The shift and coupling constant of the H-1 of fucose is especially indicative for an α -linkage of that sugar. The (1-4)linkage of fucose to the glucosamide is further corroborated by a significant upfield shift of the neighbouring C-3 of the GlcN-acyl unit far below 80 ppm when compared with the shift of the respective C-3 atom of the starting material (see preceding paper).



Scheme: Enzymatic $\alpha(1-4)$ fucosylations.

In conclusion our findings demonstrate the high promiscuity of recombinant fuc-T III with regard to the acceptor substrate. This renders the enzyme a valuable biocatalyst for the unambiguous and efficient preparation of sialyl-Lewis^a libraries for high through-put-screens. Thus another valuable tool is added to the synthetic arsenal of the glycobiologist. In combination with the results given previously for $\beta(1-4)$ galactosyl-transferase⁸, $\alpha(2-3)$ sialyl-transferase⁹ and fuc-T VI^{10,13}, thus numerous non-natural oligosaccharides may now be prepared very efficiently via biocatalysts. Evaluations concerning the combined use of non-natural donors and non-natural acceptors are in progress and will be reported in due course.

Table: All measurements in D₂O-CD₃OD (ref. D₂O: 4.80 ppm and CD₃OD: 49.00 ppm); a) d J ~ 8.5 Hz; b) dd J ~ 11.5 Hz and ~ 3 Hz; c) doublet J ~ 3 - 4 Hz; d) quartet J ~ 6.8 Hz; e) not resolved.

entry	acyl	% (mg)	GlcNacyl: H-1 ^{a)} ; C-1, C-2	Gal: H-1 ^{a)} ; C-1	Sia: H-2 ^e ; C-3	Fuc: H-1 ^{c)} ; H-6 ^{d)} ; C-1, C-6	C-others: OCH ₃ , NHR
1		97 (8.4)	4.38; 102.37; 57.48	4.35; 104.63	2.79; 42.49	4.96; 1.12; 99.61; 16.60	51.98; 23.63
2		78 (8.5)	4.42; 103.06; 59.81	4.42; 104.69	2.78; 42.42	4.98; 1.11; 99.48; 16.64	51.97; 134.79
3		52 (7.3)	4.62; 101.91; 59.91	4.38; 103.83	2.83; 42.12	4.97; 1.13; 99.53; 16.73	52.06; 159.66
4		100 (6.4)	4.69; 102.29; 58.34	4.42; 103.67	2.70; 41.88	5.01; e); 99.50; 16.70	51.96; 120.07
5		87 (14.8)	4.46; 102.05; 58.41	4.22; 103.69	2.78; 42.16	5.01; 1.13; 99.51; 16.72	51.96; 159.87
6		56 (6.8)	4.44; 102.17; 58.80	4.31; 103.72	2.74; 41.93	4.99; e); 99.51; 16.71	51.96; 127.55
7		70 (12.1)	4.69; 102.46; 58.54	4.48; 103.75	2.69; 41.67	5.01; 1.10; 99.59; 16.72	51.94; 148.99
8		80 (13.4)	4.56; 101.66; 58.26	4.43; 104.12	2.75; 41.51	5.03; 1.13; 99.55; 16.67	51.98; 176.12
9		52 (9.0)	4.64; 102.78; 57.98	4.49; 103.49	2.61; 41.56	5.03; e) 99.96; 16.72	51.93; 120.55
10		76 (19.7)	4.60; 102.69; 58.14	4.49 103.64	2.67; 41.70	5.02; e); 99.59; 16.71	51.91; 114.84

Representative experimental procedure: To a mixture of 600 µl of bidistilled water, 450 µl of Na-cacodylate buffer (250 mM, pH = 6.5) and 150 µl of a 250 mM MnCl₂-solution are added 14.8 mg (15.8 µmol) of trisaccharide **1** (entry 5), 13.8 mg (21.7 µmol) GDP-fuc¹⁶ and 2.1 mg of bovine serum albumine (Boehringer). The clear mixture is incubated at 37°C in a plastic tube with 120 µl (720 mU) fuc-T III and 3 µl (51 U) of calf intestine alkaline phosphatase (Boehringer no. 108146, 7500 U/ 498 µl). After a TLC (CH₂Cl₂ - Methanol - water mixtures) shows the consumption of the starting acceptor **1**, the turbid solution is centrifuged and the clear supernatant passed over a C-18 reversed-phase column, washed with water, eluted with methanol and finally purified over silica-gel (CH₂Cl₂ - Methanol - water mixtures). Lyophilization from dioxane-water yields 14.8 mg (87%) of compound **3** (entry 5) as a white powder which is pure according MS-, ¹H- and ¹³C NMR-analysis.

References:

- 1) Molecular Glycobiology, ed. by M. Fukuda, O. Hindsgaul, Oxford University Press **1994**.
- 2) Z. J. Witzak, Curr. Med. Chem. **1995**, *1*, 392.
- 3) R. A. Dwek, Chem. Rev. **1996**, *96*, 683.
- 4) J. C. McAuliffe, O. Hindsgaul, Chem. & Ind. **1997**, *3*, 170.
- 5) C.-H. Wong, R. L. Halcomb, Y. Ichikawa, T. Kajimoto, Angew. Chem. Int. Ed. Engl. **1995**, *34*, 521.
- 6) M. M. Palcic, O. Hindsgaul, TIGG **1996**, *8*, 37.
- 7) G. Baisch, R. Öhrlein, B. Ernst, Bioorg. Med. Chem. Lett. **1996**, *6*, 749.
- 8) G. Baisch, R. Öhrlein, M. Streiff, B. Ernst, Bioorg. Med. Chem. Lett. **1996**, *6*, 755.
- 9) G. Baisch, R. Öhrlein, A. Katopodis, B. Ernst, Bioorg. Med. Chem. Lett. **1996**, *6*, 759.
- 10) G. Baisch, R. Öhrlein, A. Katopodis, Bioorg. Med. Chem. Lett. **1996**, *24*, 2953.
- 11) G. Baisch, R. Öhrlein, A. Katopodis, M. Streiff, F. Kolbinger, Biorg. Med. Chem. Lett. in press
- 12) G. Srivastava, K. J. Kaur, O. Hindsgaul, M. M. Palcic, J. Biol. Chem. **1992**, *267*, 22356.
- 13) G. Baisch, R. Öhrlein, A. Katopodis, Biorg. Med. Chem. Lett. in press.
- 14) K. Sasaki, K. Kurata, K. Funayama, M. Nagata, E. Watanabe, S. Ohta, N. Hanai, T. Nishi, J. Biol. Chem. **1994**, *269*, 14730.
- 15) P. V. Nikrad, M. A. Kashem, K. B. Wlasichuk, G. Alton, A. P. Venot, Carbohydr. Res. **1993**, *250*, 145.
- 16) G. Baisch, R. Öhrlein, Biorg. Med. Chem. **1997**, *5*, 383.
- 17) M. M. Palcic, Methods Enzymol. **1994**, *230*, 300.